Clinical trial
A Double-blind, Randomized, Placebo-controlled, Phase 2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamic (PD) Effects of Two Infusions of Escalating Doses of TPM502 in Adults Diagnosed With Celiac Disease
NCT05660109 is registered in ClinicalTrials.gov with Topas Therapeutics GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled, Phase 2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamic (PD) Effects of Two Infusions of Escalating Doses of TPM502 in Adults Diagnosed With Celiac Disease
- Lead sponsor
- Topas Therapeutics GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 12, 2022
- Completion date
- August 8, 2024
- Enrollment
- 28 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.